An agent-based model of inflammation and fibrosis following particulate exposure in the lung

Mathematical Biosciences

Volumn 231, Issue 2, 2011, Pages 186-196

  Brown, Bryan N ^a,b   Price, Ian M ^a   Toapanta, Franklin R ^a   DeAlmeida, Dilhari R ^a   Wiley, Clayton A ^c   Ross, Ted M ^a,c   Oury, Tim D ^c   Vodovotz, Yoram ^a,b,d  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b University of Pittsburgh   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Agent based model; Fibrosis; Lung; Systems biology

Indexed keywords

AGENT-BASED MODEL; AIRWAY REMODELING; ANTI-INFLAMMATORIES; COLLAGEN DEPOSITION; CYTOKINES; FIBROSIS; IN-SILICO; INFLAMMATORY CELLS; INFLAMMATORY PROCESS; LUNG; LUNG TISSUE; MODELING ASPECTS; PARTICULATE MATTER; SALIENT FEATURES; SYSTEMS BIOLOGY; TISSUE DAMAGE;

CELL CULTURE; COMPUTATIONAL METHODS; FIBROBLASTS; MACROPHAGES; PATHOLOGY; TISSUE;

BIOLOGICAL ORGANS;

COLLAGEN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

NUMERICAL MODEL; PARTICULATE MATTER; POLLUTION EXPOSURE; RESPIRATORY DISEASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INTERACTION; CIGARETTE SMOKING; COMPUTER MODEL; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; FEMALE; FIBROBLAST; HEALING; HISTOPATHOLOGY; IN VIVO STUDY; INFLAMMATORY CELL; LUNG FIBROSIS; LYMPHOCYTE; MACROPHAGE; MATHEMATICAL MODEL; MOUSE; NONHUMAN; PARTICULATE MATTER; PNEUMONIA; PREDICTION; TISSUE DISTRIBUTION; TISSUE INJURY; VALIDATION PROCESS;

ANIMALS; COMPUTER SIMULATION; INFLAMMATION; LUNG DISEASES; MICE; MODELS, BIOLOGICAL; PARTICULATE MATTER; PULMONARY FIBROSIS;

MUS;

EID: 79954652304     PISSN: 00255564     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mbs.2011.03.005     Document Type: Article

References (98)

1. Yoshida T., Tuder R.M. Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease. Physiol. Rev. 2007, 87:1047.
2. Sethi J.M., Rochester C.L. Smoking and chronic obstructive pulmonary disease. Clin. Chest Med. 2000, 21:67.
3. A.D. Lopez, Disease Control Priorities Project, Global burden of Disease and Risk Factors, Oxford University, New York, NY, World Bank, Washington, DC, 2006, xxix, 475 pp.
4. Boschetto P., Quintavalle S., Miotto D., Lo Cascio N., Zeni E., et al. Chronic obstructive pulmonary disease (COPD) and occupational exposures. J. Occup. Med. Toxicol. 2006, 1:11.
5. Trupin L., Earnest G., San Pedro M., Balmes J.R., Eisner M.D., et al. The occupational burden of chronic obstructive pulmonary disease. Eur. Respir. J. 2003, 22:462.
6. Oxman A.D., Muir D.C., Shannon H.S., Stock S.R., Hnizdo E., et al. Occupational dust exposure and chronic obstructive pulmonary disease. A systematic overview of the evidence. Am. Rev. Respir. Dis. 1993, 148:38.
7. Liu S., Zhou Y., Wang X., Wang D., Lu J., et al. Biomass fuels are the probable risk factor for chronic obstructive pulmonary disease in rural South China. Thorax 2007, 62:889.
8. Liu Y., Lee K., Perez-Padilla R., Hudson N.L., Mannino D.M. Outdoor and indoor air pollution and COPD-related diseases in high- and low-income countries. Int. J. Tuberc. Lung Dis. 2008, 12:115.
9. Medina-Ramon M., Zanobetti A., Schwartz J. The effect of ozone and PM10 on hospital admissions for pneumonia and chronic obstructive pulmonary disease: a national multicity study. Am. J. Epidemiol. 2006, 163:579.
10. Schikowski T., Sugiri D., Ranft U., Gehring U., Heinrich J., et al. Long-term air pollution exposure and living close to busy roads are associated with COPD in women. Respir. Res. 2005, 6:152.
11. Maier K.L., Alessandrini F., Beck-Speier I., Hofer T.P., Diabate S., et al. Health effects of ambient particulate matter - biological mechanisms and inflammatory responses to in vitro and in vivo particle exposures. Inhal. Toxicol. 2008, 20:319.
12. Green F.H., Vallyathan V., Hahn F.F. Comparative pathology of environmental lung disease: an overview. Toxicol. Pathol. 2007, 35:136.
13. Fraig M., Shreesha U., Savici D., Katzenstein A.L. Respiratory bronchiolitis: a clinicopathologic study in current smokers, ex-smokers, and never-smokers. Am. J. Surg. Pathol. 2002, 26:647.
14. Di Stefano A., Capelli A., Lusuardi M., Balbo P., Vecchio C., et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am. J. Respir. Crit. Care Med. 1998, 158:1277.
15. Hogg J.C., Chu F., Utokaparch S., Woods R., Elliott W.M., et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004, 350:2645.
16. Larsson K. Aspects on pathophysiological mechanisms in COPD. J. Intern. Med. 2007, 262:311.
17. Mannino D.M., Davis K.J. Lung function decline and outcomes in an elderly population. Thorax 2006, 61:472.
18. Lundback B., Lindberg A., Lindstrom M., Ronmark E., Jonsson A.C., et al. Not 15 but 50% of smokers develop COPD? - report from the obstructive lung disease in Northern Sweden studies. Respir. Med. 2003, 97:115.
19. Kent L., Smyth L., Clayton C., Scott L., Cook T., et al. Cigarette smoke extract induced cytokine and chemokine gene expression changes in COPD macrophages. Cytokine 2008.
20. Siafakas N.M., Tzortzaki E.G. Few smokers develop COPD. Why?. Respir. Med. 2002, 96:615.
21. Kim K.M., Park S.H., Kim J.S., Lee W.K., Cha S.I., et al. Polymorphisms in the Type IV Collagen Alpha3 Gene and the risk of COPD. Eur. Respir. J. 2008.
22. Celedon J.C., Lange C., Raby B.A., Litonjua A.A., Palmer L.J., et al. The transforming growth factor-beta1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). Hum. Mol. Genet. 2004, 13:1649.
23. Keatings V.M., Cave S.J., Henry M.J., Morgan K., O'Connor C.M., et al. A polymorphism in the tumor necrosis factor-alpha gene promoter region may predispose to a poor prognosis in COPD. Chest 2000, 118:971.
24. Stoller J.K., Aboussouan L.S. Alpha1-antitrypsin deficiency. Lancet 2005, 365:2225.
25. Barnes P.J. Immunology of asthma and chronic obstructive pulmonary disease. Nat. Rev. Immunol. 2008, 8:183.
26. Barnes P.J. Alveolar macrophages as orchestrators of COPD. COPD 2004, 1:59.
27. Alcorn J.F., Crowe C.R., Kolls J.K. TH17 cells in asthma and COPD. Annu. Rev. Physiol. 2010, 72:495.
28. Cornwell W.D., Kim V., Song C., Rogers T.J. Pathogenesis of inflammation and repair in advanced COPD. Semin. Respir. Crit. Care Med. 2010, 31:257.
29. Lane N., Robins R.A., Corne J., Fairclough L. Regulation in chronic obstructive pulmonary disease: the role of regulatory T-cells and Th17 cells. Clin. Sci. (Lond.) 2010, 119:75.
30. Prasse A., Pechkovsky D.V., Toews G.B., Jungraithmayr W., Kollert F., et al. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am. J. Respir. Crit. Care Med. 2006, 173:781.
31. Harari S., Caminati A. IPF: new insight on pathogenesis and treatment. Allergy 2010, 65:537.
32. Selman M., Pardo A. The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2003, 29:S93.
33. Selman M., Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc. Am. Thorac. Soc. 2006, 3:364.
34. Ichinose M. Differences of inflammatory mechanisms in asthma and COPD. Allergol. Int. 2009, 58:307.
35. Wright J.L., Churg A. Animal models of COPD: barriers, successes, and challenges. Pulm. Pharmacol. Ther. 2008.
36. Martorana P.A., Cavarra E., Lucatteli M., Lungarella G. Models for COPD involving cigarette smoke. Drug Discov. Today: Dis. Models 2006, 3:225.
37. Fujita M., Nakanishi Y. The pathogenesis of COPD: lessons learned from in vivo animal models. Med. Sci. Monit. 2007, 13:RA19.
38. Vodovotz Y., Clermont G., Chow C., An G. Mathematical models of the acute inflammatory response. Curr. Opin. Crit. Care 2004, 10:383.
39. Vodovotz Y., Csete M., Bartels J., Chang S., An G. Translational systems biology of inflammation. PLoS Comput. Biol. 2008, 4:e1000014.
40. An G., Faeder J., Vodovotz Y. Translational systems biology: introduction of an engineering approach to the pathophysiology of the burn patient. J. Burn. Care Res. 2008, 29:277.
41. Vodovotz Y., Constantine G., Rubin J., Csete M., Voit E.O., et al. Mechanistic simulations of inflammation: current state and future prospects. Math. Biosci. 2009, 217:1.
42. An G., Mi Q., Dutta-Moscato J., Vodovotz Y. Agent-based models in translational systems biology, Wiley Interdiscip. Rev. Syst. Biol. Med. 2009, 1:159.
43. Li N.Y., Verdolini K., Clermont G., Mi Q., Rubinstein E.N., et al. A patient-specific in silico model of inflammation and healing tested in acute vocal fold injury. PLoS One 2008, 3:e2789.
44. Mi Q., Riviere B., Clermont G., Steed D.L., Vodovotz Y. Agent-based model of inflammation and wound healing: insights into diabetic foot ulcer pathology and the role of transforming growth factor-beta1. Wound Repair Regen. 2007, 15:671.
45. Xiong Z., Leme A.S., Ray P., Shapiro S.D., Lee J.S. CX3CR1+ lung mononuclear phagocytes spatially confined to the interstitium produce TNF-{alpha} and IL-6 and promote cigarette smoke-induced emphysema. J. Immunol. 2011, 186:3206.
46. Auffray C., Fogg D., Garfa M., Elain G., Join-Lambert O., et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 2007, 317:666.
47. Fletcher C., Peto R., Tinker R., Speizer F.E. The Natural History of Chronic Bronchitis and Emphysema 1976, Oxford University, Oxford.
48. Wise R.A., Kanner R.E., Lindgren P., Connett J.E., Altose M.D., et al. The effect of smoking intervention and an inhaled bronchodilator on airways reactivity in COPD: the lung health study. Chest 2003, 124:449.
49. Hodge S., Hodge G., Holmes M., Reynolds P.N. Increased airway epithelial and T-cell apoptosis in COPD remains despite smoking cessation. Eur. Respir. J. 2005, 25:447.
50. Alexis N.E., Lay J.C., Zeman K., Bennett W.E., Peden D.B., et al. Biological material on inhaled coarse fraction particulate matter activates airway phagocytes in vivo in healthy volunteers. J. Allergy Clin. Immunol. 2006, 117:1396.
51. Imrich A., Ning Y., Lawrence J., Coull B., Gitin E., et al. Alveolar macrophage cytokine response to air pollution particles: oxidant mechanisms. Toxicol. Appl. Pharmacol. 2007, 218:256.
52. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25:677.
53. Cavaillon J.M. Cytokines and macrophages. Biomed. Pharmacother 1994, 48:445.
54. Nathan C. Points of control in inflammation. Nature 2002, 420:846.
55. Lotze M.T., Zeh H.J., Rubartelli A., Sparvero L.J., Amoscato A.A., et al. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol. Rev. 2007, 220:60.
56. Matzinger P. The danger model: a renewed sense of self. Science 2002, 296:301.
57. Chung K.F., Adcock I.M. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur. Respir. J. 2008, 31:1334.
58. Djekic U.V., Gaggar A., Weathington N.M. Attacking the multi-tiered proteolytic pathology of COPD: new insights from basic and translational studies. Pharmacol. Ther. 2008.
59. Lim S., Roche N., Oliver B.G., Mattos W., Barnes P.J., et al. Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10. Am. J. Respir. Crit. Care Med. 2000, 162:1355.
60. Russell R.E., Culpitt S.V., DeMatos C., Donnelly L., Smith M., et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 2002, 26:602.
61. Russell R.E., Thorley A., Culpitt S.V., Dodd S., Donnelly L.E., et al. Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. Am. J. Physiol. Lung Cell Mol. Physiol. 2002, 283:L867.
62. Segura-Valdez L., Pardo A., Gaxiola M., Uhal B.D., Becerril C., et al. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest 2000, 117:684.
63. Porcheray F., Viaud S., Rimaniol A.C., Leone C., Samah B., et al. Macrophage activation switching: an asset for the resolution of inflammation. Clin. Exp. Immunol. 2005, 142:481.
64. Cockbill S. Wounds: the healing process. Hosp. Pharmacist. 2002, 9:225.
65. Witte M.B., Barbul A. General principles of wound healing. Surg. Clin. North Am. 1997, 77:509.
66. Roberts A.B., Sporn M.B. Transforming growth factor- β. The Molecular and Cellular Biology of Wound Repair 1996, 275. Plenum, New York. R.A.F. Clark (Ed.).
67. Roberts A.B., Sporn M.B. The transforming growth factor-βs. Peptide Growth Factors and their Receptors 1990, 419. Springer, Berlin. M.B. Sporn, A.B. Roberts (Eds.).
68. Matthews N., Watkins J.F. Tumour-necrosis factor from the rabbit. I. Mode of action, specificity and physicochemical properties. Br. J. Cancer 1978, 38:302.
69. Bowler P.G. Wound pathophysiology, infection and therapeutic options. Ann. Med. 2002, 34:419.
70. Hautamaki R.D., Kobayashi D.K., Senior R.M., Shapiro S.D. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 1997, 277:2002.
71. Martin T.R., Frevert C.W. Innate immunity in the lungs. Proc. Am. Thorac. Soc. 2005, 2:403.
72. Aldonyte R., Jansson L., Piitulainen E., Janciauskiene S. Circulating monocytes from healthy individuals and COPD patients. Respir. Res. 2003, 4:11.
73. Martinez F.O., Sica A., Mantovani A., Locati M. Macrophage activation and polarization. Front Biosci. 2008, 13:453.
74. Mantovani A., Sica A., Locati M. Macrophage polarization comes of age. Immunity 2005, 23:344.
75. Pons A.R., Sauleda J., Noguera A., Pons J., Barcelo B., et al. Decreased macrophage release of TGF-beta and TIMP-1 in chronic obstructive pulmonary disease. Eur. Respir. J. 2005, 26:60.
76. Takanashi S., Hasegawa Y., Kanehira Y., Yamamoto K., Fujimoto K., et al. Interleukin-10 level in sputum is reduced in bronchial asthma, COPD and in smokers. Eur. Respir. J. 1999, 14:309.
77. Camoretti-Mercado B., Solway J. Transforming growth factor-beta1 and disorders of the lung. Cell. Biochem. Biophys. 2005, 43:131.
78. Koli K., Myllarniemi M., Keski-Oja J., Kinnula V.L. Transforming growth factor-beta activation in the lung: focus on fibrosis and reactive oxygen species. Antioxid. Redox Signal 2008, 10:333.
79. Takizawa H., Tanaka M., Takami K., Ohtoshi T., Ito K., et al. Increased expression of transforming growth factor-beta1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). Am. J. Respir. Crit. Care Med. 2001, 163:1476.
80. Hodge S.J., Hodge G.L., Reynolds P.N., Scicchitano R., Holmes M. Increased production of TGF-beta and apoptosis of T lymphocytes isolated from peripheral blood in COPD. Am. J. Physiol. Lung Cell. Mol. Physiol. 2003, 285:L492.
81. Beghe B., Bazzan E., Baraldo S., Calabrese F., Rea F., et al. Transforming growth factor-beta type II receptor in pulmonary arteries of patients with very severe COPD. Eur. Respir. J. 2006, 28:556.
82. de Boer W.I., van Schadewijk A., Sont J.K., Sharma H.S., Stolk J., et al. Transforming growth factor beta1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998, 158:1951.
83. Anthony Tony Cox L. A mathematical model of protease-antiprotease homeostasis failure in chronic obstructive pulmonary disease (COPD). Risk Anal. 2008.
84. Kumar R., Clermont G., Vodovotz Y., Chow C.C. The dynamics of acute inflammation. J. Theor. Biol. 2004, 230:145.
85. Kumar R., Chow C.C., Bartels J.D., Clermont G., Vodovotz Y. A mathematical simulation of the inflammatory response to anthrax infection. Shock 2008, 29:104.
86. Walgraef D. Spatio-Temporal Pattern Formation: With Examples from Physics, Chemistry, and Materials Science 1997, Springer, New York, x, 306 pp.
87. Murray J.D. Mathematical Biology 2002, Springer, New York.
88. Segovia-Juarez J.L., Ganguli S., Kirschner D. Identifying control mechanisms of granuloma formation during M. tuberculosis infection using an agent-based model. J. Theor. Biol. 2004, 231:357.
89. Taylor K.R., Trowbridge J.M., Rudisill J.A., Termeer C.C., Simon J.C., et al. Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. J. Biol. Chem. 2004, 279:17079.
90. Sarir H., Henricks P.A., van Houwelingen A.H., Nijkamp F.P., Folkerts G. Cells, mediators and Toll-like receptors in COPD. Eur. J. Pharmacol. 2008, 585:346.
91. Barbini P., Brighenti C., Cevenini G., Gnudi G. A dynamic morphometric model of the normal lung for studying expiratory flow limitation in mechanical ventilation. Ann. Biomed. Eng. 2005, 33:518.
92. Barbini P., Cevenini G., Avanzolni G. Nonlinear mechanisms determining expiratory flow limitation in mechanical ventilation: a model-based interpretation. Ann. Biomed. Eng. 2003, 31:908.
93. Yang X.L., Liu Y., Luo H.Y. Respiratory flow in obstructed airways. J. Biomech. 2006, 39:2743.
94. Vodovotz Y. Deciphering the complexity of acute inflammation using mathematical models. Immunol. Res. 2006, 36:237.
95. Marino S., Hogue I.B., Ray C.J., Kirschner D.E. A methodology for performing global uncertainty and sensitivity analysis in systems biology. J. Theor. Biol. 2008, 254:178.
96. Chow C.C., Clermont G., Kumar R., Lagoa C., Tawadrous Z., et al. The acute inflammatory response in diverse shock states. Shock 2005, 24:74.
97. Prince J.M., Levy R.M., Bartels J., Baratt A., Kane J.M., et al. In silico and in vivo approach to elucidate the inflammatory complexity of CD14-deficient mice. Mol. Med. 2006, 12:88.
98. Lagoa C.E., Bartels J., Barattm A., Tseng G., Clermont G., et al. The role of initial trauma in the host's response to injury and hemorrhage: insights from a correlation of mathematical simulations and hepatic transcriptomic analysis. Shock 2006, 26:592.